SEC Form 3 · accession 0000899243-18-017483
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. Schmid
Director
Period of report
Jun 20, 2018
Accepted (ET)
Jun 20, 2018 · 8:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 5,659 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.50 | holding | — | — | — | — | May 15, 2018 | Common Stock | 25,220 | — | D |
Explanation of responses
- F1These shares shall vest in 24 equal monthly installments
Remarks
Exhibit 24 - Power of Attorney